Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.135 USD | -3.84% | +7.40% | +19.85% |
21/03 | Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
18/03 | CLS Therapeutics Discloses its Views on Xenetic Biosciences | CI |
Sales 2024 * | 2.13M 2.67M 223M | Sales 2025 * | 1.42M 1.78M 148M | Capitalization | 5.1M 6.38M 533M |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.01M -418M | Net income 2025 * | -8M -10.01M -836M | EV / Sales 2024 * | 2.39 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.59 x |
P/E ratio 2024 * |
-1.21
x | P/E ratio 2025 * |
-5.04
x | Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.81% |
1 day | -3.84% | ||
1 week | +7.40% | ||
Current month | -3.84% | ||
1 month | -1.55% | ||
3 months | +12.52% | ||
6 months | +39.23% | ||
Current year | +19.85% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 11/16/11 | |
James F. Parslow
DFI | Director of Finance/CFO | 59 | 03/17/03 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 01/14/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 11/16/11 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 14/17/14 |
Date | Price | Change | Volume |
---|---|---|---|
01/24/01 | 4.135 | -3.84% | 3,489 |
30/24/30 | 4.3 | +7.50% | 3,284 |
29/24/29 | 4 | -2.20% | 3,998 |
26/24/26 | 4.09 | +8.32% | 667 |
25/24/25 | 3.776 | -1.92% | 1,657 |
Delayed Quote Nasdaq, May 02, 2024 at 02:00 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.85% | 6.37M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+4.19% | 22.25B | |
-14.77% | 21.68B | |
-9.07% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- XBIO Stock